spacer
home > ebr > spring 2002 > certain aspects related to shareholders' agreements in biotech companies
PUBLICATIONS
European Biopharmaceutical Review

Certain Aspects Related to Shareholders' Agreements in Biotech Companies

A biotechnology company and its management have many challenges to face these days. Research projects and the business of the company should constantly progress, but at the same time research-oriented companies need to have balanced finance for expensive research projects. It is often the case that when one financing round is completed the management has to begin planning the next. Private equity investments as well as public subsidies are often the only finance available to start-up biotechnology companies. Loans and credits from banks or other financial institutions are often too expensive sources of financing for these companies. Moreover, start-up biotechs rarely possess the necessary assets to be used as security for the bank's financing. In such cases, venture capital finance plays an important role for biotech companies.


Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
By Ben Rapinoja, Attorney at Borenius & Kemppinen Ltd

Ben Rapinoja's areas of expertise are intellectual property rights (IPR) - in particular patents, trademarks and contract law. His legal practise relates to the licensing and commercial exploitation of IPR, as well as litigation within patent, trademark and copyright law. Ben advises expanding companies in the biotechnology and pharmaceutical sectors in matters related to corporate law and contracts. He also advises companies with interests in the information technology sector.
Before joining Borenius & Kemppinen, Ben worked at the Ministry of Trade and Industry, gaining experience in IPR law. He was also a Finnish Government representative working with various groups of the European Union Council and Commission, the European Patent Organisation and international organisations specialising in IPR (such as WIPO and WTO).

spacer
Ben Rapinoja
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

ERT Virtual Visit Capabilities Keep Clinical Trials on Track during COVID-19

ERT, a global data and technology company that captures critical endpoint data while minimizing uncertainty and risk in clinical trials, today announced a Virtual Visit solution that enables the continuation of clinical trials during and after current global stay-at-home mandates. As a result of COVID-19, many clinical trials have been delayed as healthcare providers focus their efforts on patients who require urgent care, which limits clinical trial patientsí access to investigative sites for routine visits.
More info >>

White Papers

Keeping Abreast of the Competitive Environment in Clinical Development

Thomson Reuters

Strategic management of a therapy area requires hard decisions to be made about which programs to invest in and which to let go. Understanding the rapidly changing competitive environment for your drug candidates is a key input into these decisions. It is easy to lose track of the broader picture when a clinical program is in progress and get blindsided by external events.
More info >>

 
Industry Events

Formulation and Drug Delivery Series UK

8-9 July 2020, Oxford Global

This event brings together leading formulation, drug delivery and biologics manufacturing experts from around the world across two days. The panel of prominent industry leaders and world-leading scientists will share the latest case studies, innovative developments for novel therapeutic products and strategies for drug development.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement